Wright Medical upgraded to Outperform from Neutral at RW Baird As previously reported, Baird upgraded Wright Medical to Outperform from Neutral. The firm upgraded shares due to valuation, an improved position in both hammer toe and ankle replacement and expectations for accelerating organic growht. Price target is $$36.
News For WMGI From The Last 14 Days
Check below for free stories on WMGI the last two weeks.